DK0453898T3 - Anvendelse af TNF-specifikke antistoffer som lægemiddel ved behandlingen af iskæmier og deres følger - Google Patents

Anvendelse af TNF-specifikke antistoffer som lægemiddel ved behandlingen af iskæmier og deres følger

Info

Publication number
DK0453898T3
DK0453898T3 DK91105829.5T DK91105829T DK0453898T3 DK 0453898 T3 DK0453898 T3 DK 0453898T3 DK 91105829 T DK91105829 T DK 91105829T DK 0453898 T3 DK0453898 T3 DK 0453898T3
Authority
DK
Denmark
Prior art keywords
tnf
ischemia
consequences
drug
treatment
Prior art date
Application number
DK91105829.5T
Other languages
English (en)
Inventor
Peter Prof Dr Eckert
Matthias Dr Schramm
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Application granted granted Critical
Publication of DK0453898T3 publication Critical patent/DK0453898T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK91105829.5T 1990-04-25 1991-04-12 Anvendelse af TNF-specifikke antistoffer som lægemiddel ved behandlingen af iskæmier og deres følger DK0453898T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4013114 1990-04-25
DE4037604A DE4037604A1 (de) 1990-04-25 1990-11-27 Verwendung von anti-tnf-antikoerpern als arzneimittel bei der behandlung von ischaemien und deren folgen

Publications (1)

Publication Number Publication Date
DK0453898T3 true DK0453898T3 (da) 1995-10-09

Family

ID=25892502

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91105829.5T DK0453898T3 (da) 1990-04-25 1991-04-12 Anvendelse af TNF-specifikke antistoffer som lægemiddel ved behandlingen af iskæmier og deres følger

Country Status (7)

Country Link
EP (1) EP0453898B1 (da)
JP (1) JPH04364133A (da)
AT (1) ATE123226T1 (da)
DE (2) DE4037604A1 (da)
DK (1) DK0453898T3 (da)
ES (1) ES2073059T3 (da)
IL (1) IL97909A (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3443119B2 (ja) 1989-08-07 2003-09-02 ペプテック リミテッド 腫瘍壊死因子結合リガンド
US20030225254A1 (en) 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
GB9028123D0 (en) * 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
DE4307508A1 (de) * 1993-03-10 1994-09-15 Knoll Ag Verwendung von anti-TNF-Antikörpern als Arzneimittel bei der Behandlung von Herzinsuffizienz (Herzmuskelschwäche)
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US7608262B2 (en) * 1996-02-16 2009-10-27 The Kennedy Institute Of Rheumatology Methods of preventing or treating thrombosis with tumor necrosis factor antagonists
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
TW201705980A (zh) 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
NZ595225A (en) 2005-05-16 2013-05-31 Abbott Biotech Ltd Use of tnf inhibitor for treatment of erosive polyarthritis
CN102887955A (zh) 2006-04-05 2013-01-23 艾博特生物技术有限公司 抗体纯化
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2016160976A2 (en) 2015-03-30 2016-10-06 Abbvie Inc. Monovalent tnf binding proteins
EP3078675A1 (en) 2015-04-10 2016-10-12 Ares Trading S.A. Induction dosing regimen for the treatment of tnf alpha mediated disorders
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
JOP20190162A1 (ar) 2016-12-30 2019-06-27 Biocad Joint Stock Co تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8805792D0 (en) * 1988-03-11 1988-04-13 Celltech Ltd Medicaments
NZ229922A (en) * 1988-07-18 1992-04-28 Chiron Corp Monoclonal antibodies specifically binding cachectin (tumor necrosis factor) and compositions

Also Published As

Publication number Publication date
JPH04364133A (ja) 1992-12-16
IL97909A0 (en) 1992-06-21
EP0453898A3 (en) 1991-12-18
ATE123226T1 (de) 1995-06-15
IL97909A (en) 1997-09-30
ES2073059T3 (es) 1995-08-01
EP0453898A2 (de) 1991-10-30
DE4037604A1 (de) 1991-10-31
EP0453898B1 (de) 1995-05-31
DE59105609D1 (de) 1995-07-06

Similar Documents

Publication Publication Date Title
DK0453898T3 (da) Anvendelse af TNF-specifikke antistoffer som lægemiddel ved behandlingen af iskæmier og deres følger
ATE148130T1 (de) Typ-iv-dipeptidyl-aminopeptidase-inhibitoren
FI935778A7 (fi) HIV-proteaasin inhibiittoreita, jotka ovat hyödyllisiä AIDSin hoitoa varten
NO965378D0 (no) Pyrazolo- og pyrolopyridiner
FI906212A7 (fi) HIV-proteaasin inhibiittoreita, jotka ovat käyttökelpoisia AIDSin hoidossa
FI923158A7 (fi) HIV-proteaasin inhibiittoreita, jotka ovat hyödyllisiä AIDSin hoidossa
OA08724A (fr) Treatment of human viral infections by dsRNA combined with viral inhibitors.
FI981591A7 (fi) AIDS:n hoidossa käyttökelpoisia HIV-proteaasi-inhibiittoreita
NO963860L (no) Isoprenyl-transferase-inhibitorer
DK0755249T3 (da) Anvendelse af Maillard-reaktionsinhibitor til behandling af amyloidose-baseret sygdom
ES2123156T3 (es) Compuestos y procedimientos de inhibicion de hiv y virus semejantes.
FI935780A7 (fi) HIV-proteaasin inhibiittoreita, jotka ovat hyödyllisiä AIDSin hoitoa varten
MX9203629A (es) Composiciones de anticuerpos monoclonales para el tratamiento profilactico o terapeutico de infecciones bacterianas debidas a estreptococos del grupo b.
DK1242119T3 (da) Kombinationer til behandling af DNA-virale infektioner omfattende et loop-diuretikum og et hjerteglycosid
FI935779L (fi) HIV-proteaasin inhibiittoreita, jotka ovat hyödyllisiä AIDSin hoitoa varten
ATE235915T1 (de) Behandlung von hämorrhagischem virusfieber mit protein c
NZ306443A (en) Vaccine for treating chlamydia comprising momp protein from chlamydia in conjunction with 3d-mpl and qs21
ATE253578T1 (de) Oxazinochinolone zur behandlung von viralen infektionen
EP0647138A4 (en) POLYPEPTIDES AVAILABLE FROM FASCIOLA SPECIES, AND VACCINE, THERAPY PROCEDURES AND DNA SEQUENCES ENCODING THESE PEPTIDES.
DK0633928T3 (da) Mikroorganismer, deres fremstilling og anvendelse
DK1253935T3 (da) Anvendelse af placenta-vækstfaktor til forebyggelse eller behandling af iskæmiske sygdomme eller slagtilfælde
RU2002135207A (ru) Средство "арголит" для лечения инфицированных ран
ATE255594T1 (de) Hepatitis b inhibitoren
FI952018A7 (fi) BHAP-yhdisteiden käyttö yhdessä muiden ei-nukleosidi-käänteistransskri ptaasi-inhibiittoreiden kanssa HIV-infektion hoitoon
DK1368478T3 (da) Polypeptid, der fremkalder HIV-neutraliserende antistoffer